Conference Summary


Release date: November 7, 2008
for quarter ending: September 30, 2008 (3rd quarter)

I own this
Forward-looking statements

Please note: No analyst conference was held, but see my article on the recent conference on the Provenge interim results.

Overview: Now waiting for Provenge complete results. Spending way too much money per quarter given they have just 1 trial they really need to complete.

Basic data (GAAP):

Revenue was $26,000.

Net loss was $26.8 million.

EPS negative $0.29.



Conference Highlights:

Included in the net loss was a $9.1 million non-cash charge representing an increase in the fair value of warrants issued on April 3, 2008.

Cash and equivalents ended at $106.6 millon. After the end of the quarter Dendreon took $19.8 million from an equity line of credit.

IMPACT Provenge interim results for men with metastatic androgen-independent prostate cancer showed a 20% reduction in the risk of death relative to palcebo. [Not in press release, but at prior conference management indicated most likely this rate of reduction will rise in the final analysis, to a level that would ensure FDA approval]

Two further Phase 2 Provenge trials for prostate cancers were initiated in the quarter. Preclinical data from D-3263, a potential cancer therapy, was presented during the quarter.

Final results should be around middle of 2009.



Dendreon Main Page
Dendreon corporate investor page
OpenIcon Analyst Conference Summaries Main Page



More Analyst Conference Pages:


Disclaimer: Our analyst summaries may include both our condensations of statements made by company representatives and our own analysis. They are not covered by any warranty. We cannot guarantee anything said by company representatives is true. We try not to make errors, but it is possible. Before making or terminating an investment you should always verify any factual basis of your decision.

Copyright 2008 William P. Meyers